Current approaches to hormone therapy of prostate cancer
N.V. Vorobyov1, I.A. Taraki1, A.G. Muradyan1,2
1 Moscow Scientific Oncological Institute named after P. A. Herzen — a branch of “National Medical Research Center of Radiology”
2 RUDN University, Moscow
As a rule, prostate cancer is diagnosed basing on the increased value of prostate specific antigen (PSA), digital rectal examination (DRE), and prostate biopsy with an assessment of the lesion area in positive biopsies and tumor differentiation (Gleason scale).
Prostate cancer (PCa) in many countries ranks second in the structure of oncological morbidity, that confirms the need to study new and optimize the already existing approaches to treatment. Androgen deprivation is currently the standard of treatment and is very important because of the sensitivity of prostate cancer cells to androgens. Approximately 50% of patients with prostate cancer receive hormone therapy at certain stages of treatment. Despite several decades of clinical application, there are still many disputes over the approaches to androgen deprivation (surgical or medicamental), the time of initiating the hormone therapy (immediate or delayed), the point of application of hormone therapy (hormone therapy in maximum androgen blockade or mono mode), as well as the duration and scheme of hormonal therapy (constant or intermittent therapy). In this review, different approaches to the treatment of prostate cancer are considered depending on the form of the disease and the concomitant diseases, conditions and complications; a description of scientific research in this field is provided.
For citation: Vorobyov N.V., Taraki I.A., Muradyan A.G. Current approaches to hormone therapy of prostate cancer // RMJ. Medical Review. 2018. № 6. P. 36–40.
References
1. Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2018. 250 c. [Kaprin A.D., Starinskij V. V., Petrova G. V. Zlokachestvennye novoobrazovanija v Rossii v 2016 godu (zabolevaemost’ i smertnost’). M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii. 2018. 250 s. (in Russian)].
2. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2015. Vol. 136 № 5. P. E359–E386.
3. Bolla M., Poppel H. Management of prostate cancer: a multidisciplinary approach // Cham, Switzerland: Springer International Publishing. 2017. 422 p.
4. Meng M. V., Grossfeld G. D., Sadetsky N. et al. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer // Urology. 2002. Vol. 60. № 3. Suppl 1. P.7–11.
5. Wong Y.-N., Freedland S.J., Egleston B. et al. The role of primary androgen deprivation therapy in localized prostate cancer // Eur. Urol. NIH Public Access. 2009. Vol. 56. № 4. P.609–616.
6. Lu-Yao G., Albertsen P. C., Stamford J. L. et al. Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer // JAMA. 2008. Vol. 300. № 2. P.173.
7. Wirth M. P., See W. A., McLeod D.G. et. al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years // J. Urol. 2004. Vol. 172. № 5. Pt 1. P.1865–1870.
8. Studer U. E., Collette L., Whelan P. et al. Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891) // Eur. Urol. 2008. Vol. 53. № 5. P.941–949.
9. Widmark A. Klepp O., Solberg A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial // Lancet. 2009. Vol. 373. № 9660. P.301–308.
10. Mason M. D. Parulekar W. R., Sydes M. R. et al. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer // J. Clin. Oncol. 2015. Vol. 33. № 19. P.2143–2150.
11. Aoun F. Bourgi A., Ayoub E. et al. Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence // Ther. Adv. Urol. SAGE Publications, 2017. Vol. 9. № 3–4. P.73–80.
12. Lee R. T. Prostate Cancer // Integr. Med. 2018. P.790–799.
13. Roehl K. A. Han M., Ramos C. G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results // J. Urol. 2004. Vol. 172. № 3. P.910–914.
14. Freedland S. J. Humphreys E. B., Mangold L. A. et al. Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy // JAMA. 2005. Vol. 294. № 4. P.433.
15. Kupelian P. A. Mahadevan A., Reddy C. A. et al. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer // Urology. 2006. Vol. 68. № 3. P.593–598.
16. Amling C. L. Bergstralh E. J., Blute M. L. et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? // J. Urol. 2001. Vol. 165. № 4. P.1146–1151.
17. Roach M. Hanks G., Thames Jr. H. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference // Int. J. Radiat. Oncol. 2006. Vol. 65. № 4. P.965–974.
18. Briganti A. et al. Natural history of surgically treated high-risk prostate cancer // Urol. Oncol. Semin. Orig. Investig. 2015. Vol. 33. № 4. P.163.e7–163.e13.
19. Heidenreich A., Bastian P. J., Bellmunt J. et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer // Eur. Urol. 2014. Vol. 65. № 2. P.467–479.
20. Wiegel T., Bartkowiak D., Bottke D. et al. Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96–02 Trial // Int. J. Radiat. Oncol. 2015. Vol. 91. № 2. P.288–294.
21. Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer // Eur. Urol. 2017. Vol. 71. № 4. P.630–642.
22. Bosco C., Bosnyak Z., Malmberg A. et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis // Eur. Urol. 2015. Vol. 68. № 3. P.386–396.
23. Nead K. T., Boldbaatar N., Yang D. D. et al. Association of Androgen Deprivation Therapy and Thromboembolic Events: a Systematic Review and Meta-Analysis. // Urology. 2018. Apr. Vol. 114. P.155–162. doi: 10.1016/j.urology.2017.11.055.
24. Gandaglia G., Sun M., Hu J. C. et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer // Eur. Urol. 2014. Vol. 66. № 6. P.1125–1132.
25. Nicholas D. J., Melissa R. Spears, Clarke N. W. et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial // (MRC PR08, CRUK / 06 / 019). 2015. Vol. 67. P.1028–1038.
26. Glass T. R. et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning // 2003 Jan. Vol. 169. P.164–169.
27. Sweeney C. J., Chen Y. H., Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer // N. Engl. J. Med. 2015 Aug 20. Vol. 373. № 8. P.1–10.
28. Gafanov R. A. Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer // Cancer Urol. 2016. Vol. 12. № 1. P.63–68.
29. Alekseev B. Y., Andrianov A. N., Kaprin A. D. Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer // Cancer Urol. 2017. Vol. 13. № 4. P.85–90.
30. James N. D., Sydes M. R., Clarke N. W. et al. Addition of docetaxel, zoledronic acid, or both to fi rst-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2015. Vol. 6736. № 15. P.1–15.
31. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial // Lancet Oncol. Elsevier Ltd. 2004. Vol. 14. № 2. P.149–158.
32. Bolla M. et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study // 2010 Nov. Vol. 11.
33. Pilepich M. V., Winter K., Lawton C. A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase iii rtog 85–31 // 2005. Vol. 61. № 5. P.1285–1290.
34. Roach M. 3rd, Bae K., Speight J. et al. Journal of c linical oncology short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate Cancer: Long-Term Results of RTOG 8610 // J. Clin. Oncol. 2008 Feb. Vol. 26. № 4. P.585–591.
35. Ciezki J. P., Klein E. A., Angermeier K. et al. A retrospective comparison of androgen deprivation (ad) vs. no ad among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy // International Journal of Radiation Oncology, Biology, Physics. 2004. Vol. 60. № 5. P.1347–1350.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
